MIDTERM IMMUNE DILATORS

Question 1

drug used to energize the immune system when it is
exhausted from fighting prolonged invasion

Answer 1

immune stimulant

Question 2

drug used to block or suppress the actions of the T
cells and antibody production

Answer 2

immune suppressant

Question 3

specific antibodies produced by a single clone of
B cells

Answer 3

monoclonal antibodies

Question 4

use of bacteria to produce chemicals normally produced by human cells

Answer 4

recombinant DNA technology

Question 5

substances naturally produced and released by human cells that have been invaded by viruses

Answer 5

Interferons

Question 6

is produced by harvesting human leukocytes.

Answer 6

Interferon alfa-n3 (Alferon N)

Question 7

produced from Chinese hamster
ovary cells

Answer 7

Interferon beta-1a (Avonex)

Question 8

s produced by Escherichia
coli bacteria.

Answer 8

Interferon gamma-1b (Actimmune)

Question 9

act to prevent virus particles from replicating inside cells.

They
also stimulate noninvaded cells to produce
antiviral proteins,

Answer 9

Interferons

Question 10

Pharmacokinetics: interferons

Answer 10

absorbed after subcutaneous or
intramuscular injection.

Question 11

Inhibits the growth of tumor cells and enhances the
immune response

Answer 11

: Interferon Alfa-2b

Question 12

communicate between lymphocytes, which stimulate cellular immunity and inhibit tumor growth

Answer 12

Interleukins

Question 13

inhibit tumor growth by increasing lymphocyte numbers and
their activity

Answer 13

Natural interleukin-2

Question 14

Indications: Metastatic renal cell carcinoma in adults, treatment of
metastatic melanoma

Answer 14

Aldesleukin

Question 15

used to reduce the incidence of infection in patients with bone marrow
suppression

Answer 15

colony-stimulating factors

Question 16

Increases the production of neutrophils in the bone
marrow

Answer 16

Filgrastim

Question 17

are used in conjunction with
corticosteroids, which block the inflammatory reaction and decrease initial
damage to cells.

Answer 17

Immune Suppressants

Question 18

beneficial in cases of organ
transplantation and in the treatment of autoimmune diseases

Answer 18

Immune Suppressants

Question 19

block the release of various cytokines involved in
the inflammatory response and activation of lymphocytes

Answer 19

Immune Modulator

Question 20

inhibit the secretion of
proinflammatory cytokines

Answer 20

lenalidomide and thalidomide

Question 21

inhibits the release of lymphocytes from lymph nodes into the
peripheral blood so they cannot migrate to activate immune

Answer 21

Fingolimod

Question 22

the first oral agent for the treatment of relapsing
forms of multiple sclerosis.

Answer 22

Fingolimod

Question 23

used in treating multiple
myeloma and myelodysplastic syndromes.

Answer 23

Lenalidomide

Question 24

used for
treating multiple myeloma and erythema nodosum leprosum

Answer 24

Thalidomide

Question 25

Prophylaxis for organ rejection in kidney, liver, and heart transplants

Answer 25

Cyclosporine

Question 26

The only available interleukin-1 receptor antagonist is

Answer 26

anakinra (Kineret)

Question 27

The recommended dosage of Anakinra:

Answer 27

is 100 mg/d by subcutaneous injection

Question 28

Anakinra is contraindicated with any known allergy to

Answer 28

E. coli–produced products

Question 29

Anakinra should not be combined with ____because of the potential for serious infections

Answer 29

abatacept

Question 30

first monoclonal antibody approved for use, is a Tcell–specific antibody that was available as an IV agent.

Answer 30

Muromonab-CD3

Question 31

an antibody specific for lymphocyte receptor sites.

Answer 31

Alemtuzumab

Question 32

s indicated for treatment of relapsing forms of multiple sclerosis.

Answer 32

Daclizumab

Question 33

a specific interleukin-6 blocker and is used for cryopyrin-associated periodic syndromes and juvenile arthritis.

Answer 33

Canakinumab

Question 34

an antibody to immunoglobulin E, an important factor in allergic reactions.

Answer 34

Omalizumab

Question 35

s specific to the antigenic site on respiratory syncytial virus

Answer 35

Palivizumab

Question 36

s a specific inhibitor of B-lymphocyte stimulator, which inhibits the survival of B lymphocytes

Answer 36

Belimumab

Question 37

s a human cytotoxic T-cell antigen-4–blocking antibody.

Answer 37

Ipilimumab

Question 38

an integrin blocker that inhibits the movement of T cells across the gastric mucosa

Answer 38

Vedolizumab

Question 39

Actions: Monoclonal antibody that binds to and inhibits vascular endothelial growth factor leading to decreased angiogenesis and cell proliferation.

Answer 39

Bevacizumab